Passage Bio Inc

NASDAQ:PASG   11:08:11 AM EDT
4.32
-0.18 (-4.00%)
Products

Passage Bio Inc - Cash On Hand To Fund Operations To Year-End 2023

Published: 01/10/2022 12:24 GMT
Passage Bio Inc (PASG) - Passage Bio Inc - Cash on Hand to Fund Operations to Year-end 2023.
Passage Bio Inc - Submit Investigational New Drug Application for Phase 1/2 Clinical Program for Metachromatic Leukodystrophy in Mid-2022.
Passage Bio Inc - Dose First Patients in Global Phase 1/2 Trials for Frontotemporal Dementia and Krabbe Disease in Early 2022.
Passage Bio Inc - Dose First Patients in Cohorts 2 and 3 in Gm1 Gangliosidosis Clinical Trial in Early 2022.